57 related articles for article (PubMed ID: 25312407)
21. Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept?
Murdaca G; Gulli R; Spanò F; Mandich P; Puppo F
Drug Dev Res; 2014 Nov; 75 Suppl 1():S7-S10. PubMed ID: 25381983
[TBL] [Abstract][Full Text] [Related]
22. Early effects of tumor necrosis factor inhibition on bone homeostasis after soluble tumor necrosis factor receptor use.
Lim MJ; Kwon SR; Joo K; Son MJ; Park SG; Park W
Korean J Intern Med; 2014 Nov; 29(6):807-13. PubMed ID: 25378980
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study).
Kennedy WP; Simon JA; Offutt C; Horn P; Herman A; Townsend MJ; Tang MT; Grogan JL; Hsieh F; Davis JC
Arthritis Res Ther; 2014 Oct; 16(5):467. PubMed ID: 25359150
[TBL] [Abstract][Full Text] [Related]
24. Squamous-cell carcinoma of the tongue following therapy of rheumatoid arthritis with abatacept.
Deidda A; Pisanu C; Garau D; Longu MG; Moretti MD; Sanna ME; Moretti GM; Stochino ME
Clin Case Rep; 2014 Jun; 2(3):66-9. PubMed ID: 25356250
[TBL] [Abstract][Full Text] [Related]
25. State of the art in the treatment of systemic vasculitides.
Luqmani RA
Front Immunol; 2014; 5():471. PubMed ID: 25352843
[TBL] [Abstract][Full Text] [Related]
26. Atopic Dermatitis Flare during Abatacept Therapy.
Stinco G; Bergamo S; Frattasio A; di Meo N; Trevisan G
J Cutan Med Surg; 2014 Nov; 18(6):369-70. PubMed ID: 25348756
[No Abstract] [Full Text] [Related]
27. Interleukin-6 receptor inhibition modulates the immune reaction and restores titin phosphorylation in experimental myocarditis.
Savvatis K; Müller I; Fröhlich M; Pappritz K; Zietsch C; Hamdani N; Grote K; Schieffer B; Klingel K; Van Linthout S; Linke WA; Schultheiss HP; Tschöpe C
Basic Res Cardiol; 2014; 109(6):449. PubMed ID: 25344085
[TBL] [Abstract][Full Text] [Related]
28. Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2.
Xue Y; Mei H; Chen Y; Griffin JD; Liu Q; Weisberg E; Yang J
MedComm (2020); 2023 Jun; 4(3):e254. PubMed ID: 37193304
[TBL] [Abstract][Full Text] [Related]
29. Limited efficacy of tocilizumab in adult patients with secondary hemophagocytic lymphohistiocytosis: a retrospective cohort study.
Kim JY; Kim M; Park JK; Lee EB; Park JW; Hong J
Orphanet J Rare Dis; 2022 Sep; 17(1):363. PubMed ID: 36131317
[TBL] [Abstract][Full Text] [Related]
30. Immunoregulatory therapy strategies that target cytokine storms in patients with COVID-19 (Review).
Wang X; He Z; Zhao X
Exp Ther Med; 2021 Apr; 21(4):319. PubMed ID: 33732292
[TBL] [Abstract][Full Text] [Related]
31. Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?
Frigault MJ; Nikiforow S; Mansour MK; Hu ZH; Horowitz MM; Riches ML; Hematti P; Turtle CJ; Zhang MJ; Perales MA; Pasquini MC
Blood; 2020 Jul; 136(1):137-139. PubMed ID: 32457999
[No Abstract] [Full Text] [Related]
32. Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19.
Faguer S; Del Bello A; Abravanel F; Nicolau-Travers ML; Kamar N
Ann Intern Med; 2020 Sep; 173(6):501-503. PubMed ID: 32432518
[No Abstract] [Full Text] [Related]
33. IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome.
Dufranc E; Del Bello A; Belliere J; Kamar N; Faguer S;
Crit Care; 2020 Apr; 24(1):166. PubMed ID: 32321563
[No Abstract] [Full Text] [Related]
34. Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis.
Albeituni S; Verbist KC; Tedrick PE; Tillman H; Picarsic J; Bassett R; Nichols KE
Blood; 2019 Jul; 134(2):147-159. PubMed ID: 31015190
[TBL] [Abstract][Full Text] [Related]
35. Successful Treatment of immune Reconstitution Inflammatory syndrome-related Hemophagocytic Syndrome in an HIV Patient with Primary Effusion Lymphoma.
Zorzou MP; Chini M; Lioni A; Tsekes G; Nitsotolis T; Tierris I; Panagiotou N; Rontogianni D; Harhalakis N; Lazanas M
Hematol Rep; 2016 Nov; 8(4):6581. PubMed ID: 28090281
[TBL] [Abstract][Full Text] [Related]
36. Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8+Granzyme+ T-cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosis.
Faguer S; Vergez F; Peres M; Ferrandiz I; Casemayou A; Belliere J; Cointault O; Lavayssiere L; Nogier MB; Prevot G; Huart A; Recher C; Rostaing L
Hematol Oncol; 2016 Mar; 34(1):55-7. PubMed ID: 25312407
[No Abstract] [Full Text] [Related]
37. Tocilizumab as an Adjuvant Therapy for Hemophagocytic Lymphohistiocytosis Associated With Visceral Leishmaniasis.
Rios-Fernández R; Callejas-Rubio JL; García-Rodríguez S; Sancho J; Zubiaur M; Ortego-Centeno N
Am J Ther; 2016; 23(5):e1193-6. PubMed ID: 25768375
[TBL] [Abstract][Full Text] [Related]
38. Down-regulation of CD5 expression on activated CD8+ T cells in familial hemophagocytic lymphohistiocytosis with perforin gene mutations.
Wada T; Sakakibara Y; Nishimura R; Toma T; Ueno Y; Horita S; Tanaka T; Nishi M; Kato K; Yasumi T; Ohara O; Yachie A
Hum Immunol; 2013 Dec; 74(12):1579-85. PubMed ID: 24051121
[TBL] [Abstract][Full Text] [Related]
39. Decrease of cytotoxic T cells in allergic asthma correlates with total serum immunglobulin E.
Bratke K; Haupt F; Kuepper M; Bade B; Faehndrich S; Luttmann W; Virchow JC
Allergy; 2006 Nov; 61(11):1351-7. PubMed ID: 17002713
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
